[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Arcutis Biotherapeutics Inc (ARQT)

Arcutis Biotherapeutics Inc (ARQT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,655,512
  • Shares Outstanding, K 125,083
  • Annual Sales, $ 376,070 K
  • Annual Income, $ -16,140 K
  • EBIT $ 3 M
  • EBITDA $ 6 M
  • 60-Month Beta 1.51
  • Price/Sales 7.30
  • Price/Cash Flow N/A
  • Price/Book 14.48

Options Overview Details

View History
  • Implied Volatility 78.10% (+4.99%)
  • Historical Volatility 60.96%
  • IV Percentile 77%
  • IV Rank 30.90%
  • IV High 139.00% on 03/18/26
  • IV Low 50.87% on 12/30/25
  • Expected Move (DTE 11) 1.57 (7.41%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 174
  • Volume Avg (30-Day) 259
  • Put/Call OI Ratio 0.18
  • Today's Open Interest 7,634
  • Open Int (30-Day) 8,257
  • Expected Range 19.66 to 22.80

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.04
  • Number of Estimates 3
  • High Estimate $0.09
  • Low Estimate $0.00
  • Prior Year $-0.13
  • Growth Rate Est. (year over year) +130.77%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.30 +10.03%
on 05/19/26
24.27 -12.53%
on 05/06/26
-2.19 (-9.35%)
since 05/05/26
3-Month
19.30 +10.03%
on 05/19/26
25.53 -16.84%
on 03/10/26
-2.74 (-11.43%)
since 03/05/26
52-Week
12.72 +66.90%
on 06/13/25
31.77 -33.18%
on 12/08/25
+7.72 (+57.14%)
since 06/05/25

Most Recent Stories

More News
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., June 05, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations...

ARQT : 21.23 (-3.28%)
New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical Dermatology

Expert recommendations focused on the diagnosis and management of genital psoriasis across age groups including pediatric, adult, and older populations This is the second published manuscript from the...

ARQT : 21.23 (-3.28%)
Arcutis Management to Present at Goldman Sachs 47th Annual Global Healthcare Conference

WESTLAKE VILLAGE, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in...

ARQT : 21.23 (-3.28%)
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations...

ARQT : 21.23 (-3.28%)
Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update

Q1 2026 net product revenue for ZORYVE ® (roflumilast) was $105.4 million, a 65% increase compared to Q1 2025, and a 17% decrease compared to Q4 2025 Continued strong demand for ZORYVE despite typical...

ARQT : 21.23 (-3.28%)
Arcutis Reports Tomorrow Having Already Told Investors Exactly What Growth to Expect

Barchart Research What to Expect from ARQT Earnings ARQT Generated May 5, 2026 Current Price $23.42 EPS Estimate $$-0.02 Consensus Rating Moderate Buy Average Move 7.56% Arcutis Reports Tomorrow Having...

ARQT : 21.23 (-3.28%)
Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 Months

Submission supported by data from INTEGUMENT-INFANT Phase 2 open-label study in infants aged 3 months to less than 24 months with mild to moderate atopic dermatitis Once-daily ZORYVE cream was well tolerated...

ARQT : 21.23 (-3.28%)
Arcutis’ ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines

Strong recommendation with high certainty of clinical evidence underscores proven efficacy, safety, and tolerability of ZORYVE cream as a steroid-free topical phosphodiesterase type 4 (PDE4) inhibitor...

ARQT : 21.23 (-3.28%)
Arcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026

WESTLAKE VILLAGE, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations...

ARQT : 21.23 (-3.28%)
Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales

Mr. Taylor brings a strong track record launching multiple high-profile therapies, most recently serving as Senior Vice President, Sales at Arcutis Biotherapeutics (Nasdaq: ARQT), where he led U.S. sales...

INCY : 102.38 (+1.13%)
ARQT : 21.23 (-3.28%)
PVLA : 108.67 (-5.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Arcutis Biotherapeutics Inc. is late-stage biopharmaceutical company. It is focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases. The company's product pipeline consists of ARQ-151, ARQ-154 and ARQ-252 for multiple indications, including psoriasis,...

See More

Key Turning Points

3rd Resistance Point 23.10
2nd Resistance Point 22.64
1st Resistance Point 21.94
Last Price 21.23
1st Support Level 20.78
2nd Support Level 20.32
3rd Support Level 19.62

See More

52-Week High 31.77
Fibonacci 61.8% 24.49
Fibonacci 50% 22.25
Last Price 21.23
Fibonacci 38.2% 20.00
52-Week Low 12.72

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.